Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01MZJ
|
|||
| Former ID |
DCL000154
|
|||
| Drug Name |
LR3001
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Myeloid leukaemia [ICD-11: 2B33.1; ICD-9: 208.9] | Phase 2 | [1] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Genta
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myb messenger RNA (MYB mRNA) | Target Info | . | [2] |
| KEGG Pathway | PI3K-Akt signaling pathway | |||
| HTLV-I infection | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| IL2 signaling events mediated by PI3K | ||||
| AP-1 transcription factor network | ||||
| C-MYB transcription factor network | ||||
| Notch-mediated HES/HEY network | ||||
| Reactome | Factors involved in megakaryocyte development and platelet production | |||
| WikiPathways | SIDS Susceptibility Pathways | |||
| EV release from cardiac cells and their functional effects | ||||
| Hematopoietic Stem Cell Differentiation | ||||
| Neural Crest Differentiation | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| Factors involved in megakaryocyte development and platelet production | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Pipeline report of Genta. | |||
| REF 2 | Genta obtains orphan drug designation for C-Myb Antisense (LR3001) in chronic myelocytic leukemia. Genta. 2005. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.